Merck's new sleep drug clears DEA hurdle; Adcock's turnaround will take awhile, CEO says;

@FiercePharma: Mutated poliovirus found to beat vaccine protection. Article | Follow @FiercePharma

@EricPFierce: CPhI Worldwide will host #CPhIChat to debate the future of pharma for those of you who want a piece of that. Release | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: Does Pfizer still need AstraZeneca's vaccines business? Story | Follow @CarlyHFierce

> Merck's ($MRK) newly FDA-approved insomnia drug Belsomra (surovexant) won scheduling from the Drug Enforcement Administration, clearing the way for a launch. Report

> South Africa's Adcock Ingram posted a hefty 9-month loss, thanks to writedowns on a turnaround plan and weak demand for its drugs; CEO Kevin Wakeford warned a return to profitability would take time. Report

> TWi Pharmaceuticals said it won final approval for its version of Par Pharmaceuticals' appetite stimulant for AIDS patients, Megace ES. Report

> Johnson & Johnson's ($JNJ) newly honed recruitment strategy has helped the company improve its applicant pool and reduce turnover among new hires. Report

Medical Device News

@FierceMedDev: ReShape targets U.S. approval as EU study shows major weight loss. More | Follow @FierceMedDev

@VarunSaxena2: Between new Brain project initiative and 2 recent $COV buys + $BSX's buy of Bayer's devices, peripheral devices are officially a thing. | Follow @VarunSaxena2

@EmilyWFierce: Covidien snatched up venous disease treatment developer Sapheon for an undisclosed sum. Story | Follow @EmilyWFierce

@MichaelGFierce: Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. Article | Follow @MichaelGFierce

> J&J's DePuy Synthes unit slapped with FDA Class I recall for jaw-stabilizing device. More

> Biomarker could improve early rheumatoid arthritis diagnosis. News

> ReShape targets U.S. approval as EU study shows major weight loss. Story

Biotech News

@FierceBiotech: FDA lifts a hold on one of OncoMed's cancer drug programs. Article | Follow @FierceBiotech

@JohnCFierce: Trending today - What's the #1 biotech hub for VCs? (It's still not Boston). Story | Follow @JohnCFierce

@EmilyMFierce: Canadian Immunovaccine reports positive preclinical data for Ebola vaccine. More | Follow @EmilyMFierce

> Repros gets a lift from a head-to-head testosterone study. More

> PCSK9 race heads to the finish line with Amgen's evolocumab application. Story

> Two new biotech IPOs help set the stage for the fall parade. Article

Vaccines News

> Glaxo's Ebola vaccine trial set to begin in September. Article

> Does Pfizer still need AstraZeneca's vaccines business? Story

> Advaxis teams up with Merck to test its vaccine in prostate cancer. More

> Diamyd diabetes vax, once spurned by J&J, gets an EU boost. Report

> Mutated polio virus found to beat vaccine protection. Story

Pharma Manufacturing News

> NAFTA says FDA was in its rights to ban Apotex plants. More

> Merck KGaA starts work on what will be its second-largest plant. Article

> GSK, NewLink ramp up production of Ebola drugs, even as they conduct trials. Piece

> Patheon gets U.S. biologics plants with Gallus deal. Story

> Novo buys U.S. plant ditched by Olympus. Article

And Finally... Could untreated hot flashes be a drag on the U.S. economy? A new drugmaker-funded study says so. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.